Glivek in therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome


  1. Steer E. J., Cross N. С. P. Myeloproliferative disorders with translocations of chromosome 5q31- 35: Role of the plateletderived growth factor receptor beta. Acta Haematol. 2002; 107: 113-122.
  2. Cools J., DeAngelo D. J. D., Gotlib J. et al. A tyrosine kinase created by fusion of the PDGFRA and F1P1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003; 348 (13): 1201-1214.
  3. Pardanani A., Ketterling R. P., Brockman S. R. et al. CHIC2 deletion, a surrogate for FIP1 LI-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood First Edition Paper, prepabl. Online Jul. 3, 2003; doi: 10.1182/blood-2003-051627.
  4. Bain B. Eosinophilic leukamaemias and the idiopathic hypereosinophilic syndrome. Br.J. Haematol. 1996; 95: 2-9.
  5. Wilkinson K., Velloso R. P., Lopes L. F. et al. Cloning of the t(l;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: Involvement of PDGFRB and response to imatinib. Blood First Edition Paper, prepabl. Online Aug. 7, 2003; doi: 10.1182/blood-2003-04-1150.
  6. Daryshire P. J., Shortland D., Swansbury G. J. et al. A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(l: 5) translocation. Br. J. Haematol. 1987; 66: 483-486.
  7. Luciano L., Catalano L., Sarrantonio C. et al. AlphalNF-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(l; 5). Haematologica 1999; 84: 651 - 653.
  8. Apperley J. F., Gardembas M., Melo J. V. et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 2002; 347 (7): 481-487.
  9. Vandenberghe P., Michaux L., Boogaerts M. et al. Clinical characteristics of hypereosinophilic syndromes with an interstitial 4ql2 deletion resulting in a FIP1L1-PDGFRA fusion gene. In: 8-th Congress of the EHA. Lyon 2003. abstr. 0470.
  10. Martinelli G., Malagola M., Ottaviani E. et al. Imatinib mesylate can induce molecular remission of F1P1L1-PDGFRalpha positive idiopatic hypereosinophilic syndrome. In: ASH San Diego 2003. abstr. 5063.
  11. Jorreto M., Lemos R., Doria S. et al. Response to imatinib-mesylate in chronic eosinophilic leukaemia presenting with skin lesions, eosinophilia and hyper-lgE. In: ASH. 2003. abstr. 5069.
  12. Schaller J. L., Burkland G. A. Case report: rapid and complete control of idiopatic hypereosinophilia with imatinib mesylate. Med. Gen. Med. 2001; 3 (5): 9.
  13. Gotlib J., Malone J. M., De Angelo D. J. et al. Imatinib mesylate (GLEEVEC) induces rapid and complete hematologic remissions in patients with idiopathic hypereosinophilic syndrome (HES) without evidence of BCR-ABL or activating mutations in C-KIT and platelet-derived growth factor receptor beta (PDGFR-p). ASH 2002. Blood 2002; 100 (11): abstr. 3152.
  14. Severino S. A., Pane E., Anghel G. et al. Glivec (STI 571) in idiopathic hypereosinophilic syndrome (1HS) resistant to conventional treatment. In: 7-th Congress of the EHA 2002. abstr. 1040.
  15. Ault P., Cortes J., Koller С. et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk. Res. 2002; 26: 881-884.
  16. Gleich G. J., Leiferman К. М., Pardanani A. etal. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002; 359: 1577-1578.
  17. Pardanani A., Reeder Т., Porrata L. F. et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 10 (9): 3391-3397.
  18. Cortes J., Ault P., Koller С. et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101 (12): 4714-4716.
  19. Pettier P., Planchon В., Grossi O. Complete remission with imatinib mesylate of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha. Rev. Med. Intern. 2003; 24: 542-546.
  20. Salem Z., Zalloua P. A., Chehal A. et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol. J. EHA 2003; 4: 410-412.
  21. Cross N. C. P. Philadelphia chromosome negative chronic myeloproliferative disorders: molecular and clinical aspects. Hematol. J. EHA 2002; 15-18.

Copyright (c) 2004 Nemchenko I.S., Khoroshko N.D., Turkina A.G., Vinogradova O.Y., Sokolova M.A., Abakumov E.M., Semenova E.A., Zakharova A.V., Domracheva E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies